We evaluated the efficacy of a treatment strategy in which infants with acute lymphoblastic leukemia (ALL) were stratified by their MLL gene status and then assigned to different riskbased therapies. A total of 102 patients were registered on two consecutive multicenter trials, designated MLL96 and MLL98, between 1995 and 2001 . Those with a rearranged MLL gene (MLL-R, n ¼ 80) were assigned to receive intensive chemotherapy followed by hematopoietic stem cell transplantation (HSCT), while those with germline MLL (MLL-G, n ¼ 22) were treated with chemotherapy alone. The 5-year event-free survival (EFS) rate for all 102 infants was 50.9% (95% confidence interval, 41.0-60.8%). The most prominent late effect was growth impairment, observed in 58.9% of all evaluable patients in the MLL-R group. This plan of risk-based therapy appears to have improved the overall prognosis for infants with ALL, compared with previously reported results. However, over half the events in patients with MLL rearrangement occurred before the instigation of HSCT, and that HSCT-related toxic events comprised 36.3% (8/22) of post-transplantation events, suggesting that further stratification within the MLL-R group and the development of more effective early-phase intensification chemotherapy will be needed before the full potential of this strategy is realized.
Introduction
The outcome of therapy for children with acute lymphoblastic leukemia (ALL) has markedly improved over the last four decades, to the extent that approximately 80% of affected patients are now cured. 1 However, infants with ALL, who represent 2.5-5% of all childhood ALL cases, continue to have high relapse rates and a dismal prognosis, as illustrated by recently published event-free survival (EFS) rates of 22-54%. [2] [3] [4] [5] [6] [7] [8] ALL in infancy has several distinctive clinical characteristics compared with common childhood ALL, including hyperleukocytosis, hepatosplenomegaly, central nervous system (CNS) disease and a high frequency of molecularly evident rearrangement of the MLL gene at chromosome band 11q23. [9] [10] [11] [12] Among these features, MLL gene rearrangement, found in 70-80% of infant ALL cases studied with molecular techniques, is an independent risk factor most predictive of recurrent leukemia. [13] [14] [15] The high failure rate in infants with ALL, especially those with MLL gene rearrangement, can be attributed to early relapse after remission rather than toxicity, and warrants consideration of intensified therapy. We therefore segregated infants with ALL into two subgroups according to their MLL gene status in two consecutive nationwide multicenter studies, designated MLL96 and MLL98. Infants with a rearranged MLL (MLL-R) gene received intensive chemotherapy followed by hematopoietic stem cell transplantation (HSCT), while those with a germline MLL gene were treated with standard intensive chemotherapy for ALL alone. This report updates findings published earlier [16] [17] [18] and extends the analysis to long-term side effects. By combining data from two studies with similar treatment strategies, we were able to analyze results for a relatively large cohort with this rare subtype of ALL. The additional detail on prognostic features should facilitate further risk stratification among MLL-rearranged cases, while outcome data on the increased number of patients undergoing HSCT should stimulate critical discussion of the role of this procedure in future treatment strategies for infants with ALL.
Materials and methods

Patients
Between December 1995 and December 2001, 102 consecutive infants with ALL, younger than 12 months, were registered and treated on two protocols, designated MLL96 (55 patients) and MLL98 (47 patients). These studies accrued more than 80% of all Japanese infants with ALL over the 6-year enrollment period, based on results of a nationwide surveillance study. 17 The 
Detection of MLL gene rearrangement and cytogenetic analysis
The MLL gene status of each patient was determined by Southern blot analysis and/or split-signal fluorescence in situ hybridization (FISH) as previously described. 16 Leukemic cell karyotypes were determined by cytogenetic analysis with a G-banding technique. 16 
Treatment
The details of the therapeutic regimens used in the MLL96 and MLL98 studies are described in Supplementary Tables. [16] [17] [18] Briefly, patients with rearranged MLL (MLL-R) received induction therapy and three courses of postremission intensification therapy followed by HSCT if a suitable donor was available. Patients with germline MLL (MLL-G) were assigned to a chemotherapy arm consisting of induction, consolidation and CNS prophylaxis, intensification, reinduction and maintenance phases, administered over 83-85 weeks. Except for vincristine, drug dosages on the MLL98 protocol were calculated on the basis of body surface area, while dosages on the MLL96 protocol were based on body weight. This modification increased the dosages of all antileukemic drugs used in the MLL98 study by 1.2-to 2-fold over those in the MLL96 study.
Patients in the MLL-R group underwent HSCT in first remission (CR1), if a 5 to 6/6 human leukocyte antigen-matched related donor, 6/6-matched unrelated donor or 4 to 6/6-matched unrelated cord blood donor was available. The protocolspecified conditioning regimen comprised either a total-body irradiation (TBI; 12 Gy in six fractions, twice a day on days À7 to À5) or busulfan (BU; 35 mg/m 2 /dose orally, 4 times a day on days À8 to À5) with a combination of etoposide (60 mg/kg intravenously on day À4) and cyclophosphamide (60 mg/kg intravenously on days À3 and À2). Prophylaxis for graft-vs-host disease (GVHD) consisted of either cyclosporine or tacrolimus combined with short-term methotrexate.
Evaluation of the late effects
Late effects studied included cardiac, pulmonary, renal, endocrine, dental, orthopedic, dermatologic, ophthalmologic, auditory, psychological, growth and development and occurrence of secondary malignancies. Medical records regarding these issues were reviewed by each physician of the participating centers, and these data were collected by questionnaire which was sent to each participating center.
Statistical considerations
The analysis of treatment outcome was updated on 30 September 2006, combining data from both the MLL96 and MLL98 studies because of their similar 5-year survival estimates (see Results). EFS and overall survival (OS) rates were estimated by the method of Kaplan-Meier and standard errors (s.e.) with the Greenwood formula, and then were compared with the logrank test. Confidence intervals (CIs) were computed with a 95% confidence level. The clinical, demographic and biologic features of patients were compared with w 2 tests for homogeneity. A Cox regression model was used for the multivariate analysis. P-values, when cited, are two-sided, with a value of 0.05 or less taken to indicate statistical significance.
Results
Patient characteristics
The characteristics of the patients at diagnosis are reported in Table 1 . We identified 80 patients with MLL-R and 22 with MLL-G by Southern blot analysis and/or FISH. Patients in the MLL-R group were significantly younger (median age, 4 vs 9 months, Po0.001), and had higher leukocyte counts (median, 168.4 Â 10 9 /l vs 21.8 Â 10 9 /l, Po0.001). The frequency of CNS disease (defined as more than 5 cells/mm 3 with recognizable blasts in cerebrospinal fluid) was also significantly higher in the MLL-R group. Expression of the CD10 antigen was closely Table 1 Characteristics of infants with ALL treated in the MLL96 and MLL98 studies Outcome of infant ALL in Japan D Tomizawa et al associated with MLL-R. By karyotyping analysis, 11q23 abnormalities were found in 60 of 73 evaluable cases (82.2%) in the MLL-R group, half of whom had the t(4;11)(q21;q23) abnormality. The clinical characteristics of patients enrolled in the MLL96 study were comparable to those in the MLL98 study (data not shown).
Treatment outcome Remission induction and subsequent events. The numbers and types of events are summarized in Table 2 . The overall remission induction rate was 94.1% (96/102): Remission induction rates were high in both the MLL-R and MLL-G groups: 92.5% (74/80 patients) in the MLL-R group and 100% (22/22 patients) in the MLL-G group. There was one induction death due to a fatal adenoviral infection and five induction failures in the MLL-R group. Two of the latter patients survived for 4.9 and 6.0 years, respectively, without evidence of disease after alternative therapies (either acute myeloid leukemia-directed chemotherapy or second HSCT).
Of the 74 patients in the MLL-R group who achieved CR1, 53 remained in continuous complete remission (CCR) during the postremission phase, 1 patient died of infectious pneumonia and 20 relapsed (19 with isolated marrow relapses and 1 with relapse site not specified) before reaching the timepoint of HSCT. Among these 20 relapsed patients, 12 underwent allogeneic HSCT in second remission (CR2) and 3 underwent HSCT without remission; the 5 of 12 who underwent HSCT in CR2 remain in remission for a median duration of 8.4 years (range, 5.7-10.2 years). Forty-nine of the 53 cases in CCR underwent HSCT in CR1: 2 autologous HSCT, 21 HSCT from a related (n ¼ 12) or unrelated donor (n ¼ 9) and 26-unrelated cord blood transplantation. The median time from remission to transplantation was 4 months (range, 0-9 months). Twentyseven of the 49 patients with HSCT remained in CCR at the time of analysis, 8 died in CCR (four of veno-occlusive disease, one of cytomegalovirus infection, one of bacterial sepsis, one of gastrointestinal hemorrhage due to GVHD and thrombotic microangiopathy and one of an unspecified transplant-related complication) and 14 relapsed (nine with an isolated marrow relapses, one with combined marrow/CNS relapse, two with CNS relapse, one with testicular relapse and one with relapse site not specified). Among the 14 relapsed patients, 3 continue to survive for a median duration of 7.2 years (range, 5.0-10.1 years) after subsequent HSCT, while the remaining 11 patients eventually died, mostly of relapsed disease. The four patients who lacked a suitable donor received chemotherapy only as specified by the protocol and remained in CCR for median duration of 8.7 years (range, 3.6-10.8 years).
Analysis of overall outcome. The estimated 5-year OS and EFS rates for all 102 patients were 60.5% (95% CI, 50.7-70.2%) and 50.9% (95% CI, 41.0-60.8%), respectively, after a median follow-up of 7.1 years (range, 1.5-10.8 years). Patients in the MLL-R group had a significantly worse outcome than those in the MLL-G group: 5-year OS, 50.8% (95% CI, 39.6-62.0%) vs 95.5% (95% CI, 86.6-100%) (Figure 1 , Po0.001) and 5-year EFS, 38.6% (95% CI, 27.7-49.5%) vs 95.5% (95% CI, 86.6-100%) (Figure 1, Po0.001) .
The only difference between the MLL96 and MLL98 protocols was the higher dosages of antileukemic drugs in the latter study, which was not associated with improved outcome as demonstrated by 5-year EFS rates in the MLL-R group: 35.7% (95% CI, 21.0-50.4%) in MLL96 vs 41.8% (95% CI, 25.8-57.8%) in MLL98 (P ¼ 0.67). Neither conditioning regimen received nor donor source had a significant impact on post-transplantation EFS rates among the 49 patients with a rearranged MLL gene who underwent HSCT after CR1 (Table 3) .
Treatment outcome in the MLL-R group according to prognostic factors. The prognostic impact of several potential risk factors (Table 3) was determined in the MLL-R group. Infants younger than 6 or 3 months and those with CNS disease at diagnosis had significantly worse 5-year EFS rates than did infants without these features. Gender, leukocyte count and karyotype lacked prognostic significance in this univariate analysis. Further analysis with a Cox regression model indicated that only age less than 6 months exerted independent predictive strength (data not shown).
Long-term side effects. It was possible to evaluate longterm sequelae among 57 of the all 62 survivors of infant ALL treated on the MLL96 and MLL98 studies: 39 in the MLL-R group and 18 in the MLL-G group (complete follow-up data were not available for the remaining five patients). The median age of the 57 patients at analysis was 7.7 years (range, 1.1-10.4 years). Thirty-six of the 57 patients, all in the MLL-R group, underwent HSCT. Twenty-two received the TBI-based conditioning regimen, while 14 received the non-TBI conditioning regimen. In the TBI group, four patients had undergone allogeneic HSCT twice.
Significant late effects were not observed among patients in the MLL-G group. By contrast, various late complications were observed in the MLL-R group as follows: chronic GVHD in 5; hypothyroidism in 5; short stature (defined as a height standard deviation (s.d.) score below À2.0 or a requirement for growth hormone therapy) in 23; skin abnormalities (alopecia, scleroderma, hyper-or hypo-pigmentation) in 12; fasciitis in 1; ophthalmologic complications (dry eye, corneal opacity, retinal vasculitis) in 5; pulmonary complications (interstitial pneumonia, bronchiolitis obliterans) in 6; chronic diarrhea with malnutrition in 1; dental abnormalities in 6; multiple exostosis in 1; epilepsy in 2 and neurocognitive deficits (learning Outcome of infant ALL in Japan D Tomizawa et al disability, intelligence impairment, autism) in 4. There were no cases of secondary malignancy or symptomatic chronic heart failure. Pubertal development could not be evaluated because all study patients were younger than 12 years old and had not entered puberty. The distribution of height s.d. scores is shown in Figure 2 . Median scores for the MLL-R and MLL-G subgroups were À2.49 (range, À8.05 to þ 2.92) and þ 0.05 (range, À1.00 to þ 0.90), respectively (Figure 2a, Po0.001) . In contrast to the 36 patients who underwent HSCT, height s.d. scores for the three chemotherapy-only MLL-R patients were in the normal range (À1.88, À1.57, À1.48, respectively). The median height s.d. score for patients receiving TBI-based conditioning (n ¼ 22) was À3.07 (range, À8.05 to À0.08), which was significantly lower than the median value for those given non-TBI conditioning (n ¼ 14, À1.72 (range, À6.13 to þ 2.92)) (Figure 2b , P ¼ 0.02). However, 5 of the 14 patients in the latter group had height s.d. scores below À2.0.
Discussion
The Japanese MLL96 and MLL98 clinical trials are the first published prospective studies to stratify infants with ALL by their MLL gene status. The results demonstrated clear differences in clinical features, including treatment outcome, between patients with or without an MLL gene arrangement. In most previous reports of EFS rates for infants with ALL, these two subgroups have been combined, [2] [3] [4] [5] [6] [7] [8] when results are listed according to MLL gene status or CD10 expression, the EFS rates for those with a rearranged MLL gene or negative CD10 expression range from only 21 to 40%, and generally do not exceed 30%. Thus, our overall EFS rate of 50.9% justifies the decision to stratify infants with ALL by MLL gene status, so that appropriate risk-based treatments can be applied in each group. The method for determining MLL gene status is critical to segregating patients into 'true' MLL rearranged and non-rearranged cohorts. Because 16.2% of our MLL-rearranged patients lacked abnormalities in band 11q23 by normal karyotypic analysis, we conclude that molecularly based methods such as Southern blotting or splitsignal FISH are essential in strategies to determine the accurate MLL gene status in infants with newly diagnosed ALL.
Whether allogeneic HSCT has an important role in the treatment of infants with ALL remains controversial because of the limited data on this issue. [19] [20] [21] [22] [23] [24] [25] [26] [27] Pui et al. 19 retrospectively analyzed cooperative group and individual transplant center data for children with ALL and 11q23 abnormalities, concluding that any type of HSCT was associated with a worse outcome than chemotherapy alone for t(4;11)-positive leukemia. In that study, the EFS rate for the 28 infants who underwent HSCT was only 1973%, which is extremely low compared to our results and those of Sanders et al., 27 who reported a 3-year disease-free survival rate of 42.2% among 40 infants with ALL following HSCT. However, this apparent improvement in outcome after HSCT must be interpreted with caution, since both the report of Sanders et al. and ours lack adequate retrospective or prospective control groups. Moreover, infants are the age group most vulnerable to intensive cytotoxic therapy, especially HSCT with a myeloablative preparative regimen, as illustrated by the high proportion of post-HSCT events in the current study (36.3%, 8/22) that were due to transplant-related toxicity. It is also notable that all four patients in the MLL-R subgroup, who did not receive HSCT for lack of a suitable donor, are alive without any subsequent events.
Allogeneic HSCT in infants always harbors the risk of late effects. In our analysis, 23 of 39 patients (58.9%) in the MLL-R group, especially those receiving TBI, had short stature after a median follow-up of 7.7 years. Sanders et al. 27 reported milder growth impairment in their series despite earlier treatment with a TBI-based conditioning regimen. This discrepancy may reflect the hyperfraction method of TBI used by Sanders et al., such that 15.75 Gy was given three times a day over 7 days. Whatever the Outcome of infant ALL in Japan D Tomizawa et al explanation, we would stress that severe growth impairment was also observed among patients in the non-TBI group, which may indicate that any form of conditioning regimen for infants could increase the risk of growth retardation. We observed several other serious long-term side effects, but additional follow-up is needed before the impact of these complications can be fully assessed. Besides, caution is needed to evaluate some of the late effects reported here, because there is a certain methodological limitation in collecting these data, which is questionnaire-based, that may lead to an underestimation of these events.
Several steps will need to be taken to further improve the prognosis of infant ALL with MLL gene rearrangements. First, additional risk stratification may identify important subsets of patients who would benefit from alternative therapy. Our analysis indicated that age at diagnosis can be used to segregate patients into two subgroups with different 5-year EFS rates: 27.8% for infants younger than 6 months and 52.9% for infants 6 months or older. This approach would not only contribute to better control of the leukemic clone, but might also reduce treatment-related toxicity. Second, we would emphasize that nearly half of the events (21/49) in our MLL-R group occurred before the use of HSCT. Thus, despite an initial remission rate of more than 90%, effective strategies to prevent early relapse are urgently needed. Pieters et al. 28 described the in vitro drug-resistance data, which demonstrate greater sensitivity to cytarabine (Ara-C) and higher resistance to glucocorticoids and L-asparaginase by leukemic cells from infants. In fact, we did introduce intensive use of Ara-C and dexamethasone in our treatment, which may in part have contributed to improved outcome compared to the historical data. However, one might improve results by further intensifying the early phase of postremission intensification therapy with Ara-C and with intensive use of L-asparaginase, which was not used in the current therapy, to overcome the leukemic cell drug-resistance to this agent. Third, the toxic events and late effects related to HSCT are hardly acceptable for treating infants with ALL. Without clear evidence for benefit of HSCT, it will be necessary to devise an effective chemotherapy regimen without HSCT, at least for the 'lower-risk' MLL-R subgroup. Finally, two large Outcome of infant ALL in Japan D Tomizawa et al multicenter studies investigating effective chemotherapy regimens for infant ALL (Interfant 99 and POG/COG9407) have been completed in Europe and in the United States, and these results will be important in designing future protocols for this age group, as will studies to develop innovative targeted therapies for infants with MLL-rearranged ALL, now underway. 29, 30 
